Ignite Creation Date:
2025-12-25 @ 4:30 AM
Ignite Modification Date:
2025-12-26 @ 3:33 AM
Study NCT ID:
NCT00855218
Status:
COMPLETED
Last Update Posted:
2017-08-18
First Post:
2009-03-03
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
Sponsor:
Bayer
Organization:
Study Modules
Identification Module
Status Module
Sponsor Collaborators Module
Oversight Module
Description Module
Conditions Module
Design Module
Arms Interventions Module
Outcomes Module
Eligibility Module
Contacts Locations Module
References Module
Adverse Events Module
Baseline Characteristics Module
Participant Flow Module